Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03476109
Other study ID # 2017/19JUI/325
Secondary ID PNEU-ASTHMA-0220
Status Recruiting
Phase Phase 4
First received
Last updated
Start date May 10, 2019
Est. completion date December 31, 2024

Study information

Verified date October 2022
Source Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Contact Charles Pilette, MD PhD
Phone 003227642866
Email charles.pilette@uclouvain.be
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Pragmatic trial to define the magnitude and the predictive factors of the response to omalizumab and mepolizumab in adult patients with severe refractory asthma and eligible to both therapies.


Description:

Title "PREDICTUMAB: Predictive factors and magnitude of response to omalizumab and mepolizumab in allergic and eosinophilic severe asthma: a multicenter, open, active-controlled, randomized trial in adult patients in Belgium". Rationale and background New treatments are now available to treat severe refractory asthma, which affects about 3 to 5% of asthma patients. In particular, biological therapies using monoclonal antibodies targeted to immunoglobulin E (IgE) or interleukin (IL)-5 (and in the future other cytokines or growth factors) benefit to certain patients. Identifying those patients who will better benefit from a specific treatment requires the validation of features (clinical traits, biomarkers) that are predictive of the therapeutic outcome. Such predictive strategy is not available to decide whether anti-IgE (omalizumab) or anti-IL-5 (mepolizumab) should be prioritized in patients who are eligible to both therapies. In addition, the comparison of the magnitude of the clinical benefits achieved by these therapies remains unexplored in this population. Study Design The study is designed to initially randomly allocate patients from two strata (with or without maintenance oral corticosteroids) to oma- vs mepolizumab. According to the evaluation of response (at 4 or 6 months, respectively), subjects will then be either prolonged (for 12 months, for both therapies) on the same therapy, or switched to the other. For those who were switched, treatment will be prolonged (or not, in dual failers) after 4 or 6 months according to their evaluation of response. Time-points for analysis will be at 4 or 6 months, 10 months (interim analysis) and 18 or 22 months (final, posttreatment analysis). State-of-the-art Asthma is one of the most frequent chronic diseases, affecting 5 to 10% of the population worldwide. Omalizumab and mepolizumab represent the approved antibodies that are indicated in allergic and eosinophilic phenotypes of severe asthma respectively. However, if some patients fall into only one phenotypic category based on these criteria, a substantial number of patients are potentially eligible to both therapies. In those patients, no information is available to orientate towards a preferable therapy as the predictive weight of additional phenotypic traits, such as associated nasal polyps or early- versus late onset of disease, remains unknown. In addition, no head-to-head comparison of these therapies is available in this population. Objectives of the study Primary objectives To determine clinical features and blood (or sputum) biomarkers able to predict a better response to omalizumab or mepolizumab in severe asthma patients eligible to both therapies. To determine the magnitude of response, in terms of improvement in symptoms, exacerbation rate and/or lung function, in responders to omalizumab vs mepolizumab. Secondary objectives To compare the global baseline characteristics (clinical and biological features) of patients responding to omalizumab vs mepolizumab. Management and reporting of adverse events. If during the study, an adverse event (AE) (serious or non-serious) is identified as attributed to omalizumab or mepolizumab, this will be documented as appropriate in routine good clinical practice, to the Federal Agency of Medicines and Products of Health (AFMPS) as well as to the Central Ethic Committee. Confidentiality of data. The identity and participation of subjects will remain strictly confidential, according to Belgian laws dated 8 Dec 1992 related to the protection of private life and dated 22 Aug 2002 related to patient rights. Specimens and associated data will be labeled with unique patient identification number. Data will be anonymized in all files, results and publications related to the study. The promoter confirms to authorize the regulatory surveillance, examination and controls by competent authorities, by allowing direct access to database/files, and this in full respect of confidentiality.


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date December 31, 2024
Est. primary completion date December 31, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: • Signed informed consent form (ICF), - Age >18+ years at time of signing ICF, - Able to comply with the study protocol, in the investigator's judgment, - Documented physician-diagnosed asthma , - Patients with severe disease and eligible to omalizumab and mepolizumab, and who have not yet received any of these therapies. Exclusion Criteria: - History of evidence of drug/substance abuse that would pose a risk to patient safety, interfere with the conduct of study, have an impact on the study results, or affect the patient's ability to participate in the study, in the opinion of the investigator - Treatment with any investigational therapy within 6 months or 5 drug half-lives prior to enrolment. - Known sensitivity to any of the active substances or their excipients to be administered during the study.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Randomisation to omalizumab
The only intervention will be that allocation of patients to omalizumab or mepolizumab (to both of which patients will be eligible) will be randomized, to avoid that the initial decision is biased by confounding factors that are likely, but unproven, to affect the treatment response. Then, in case of non-response, patients will be switched to the other drug, as routine clinical practice would indicate.
Randomisation to mepolizumab
The only intervention will be that allocation of patients to omalizumab or mepolizumab (to both of which patients will be eligible) will be randomized, to avoid that the initial decision is biased by confounding factors that are likely, but unproven, to affect the treatment response. Then, in case of non-response, patients will be switched to the other drug, as routine clinical practice would indicate.

Locations

Country Name City State
Belgium Universitair Ziekenhuis Brussel Brussel Brussels
Belgium Cliniques universitaires St-Luc Brussels
Belgium Brugmann University Hospital Bruxelles
Belgium Centre Hospitalier Universitaire Saint Pierre Bruxelles
Belgium Erasme University Hospital Bruxelles
Belgium CHU de Charleroi Charleroi Hainaut
Belgium Grand Hôpital de Charleroi Charleroi Hainaut
Belgium University Hospital, Ghent Gent
Belgium Katholieke Universiteit Leuven Leuven Vlaams Brabant
Belgium University Hospital of Liege Liège
Belgium Centre Hospitalier Universitaire Dinant Godinne - UCL Namur Namur
Belgium CHR Namur Namur
Belgium AZ Delta Roeselare Roeselare West-vlaanderen

Sponsors (12)

Lead Sponsor Collaborator
Cliniques universitaires Saint-Luc- Université Catholique de Louvain AZ Delta, Brugmann University Hospital, Centre Hospitalier Universitaire Dinant Godinne - UCL Namur, Centre Hospitalier Universitaire Saint Pierre, CHU de Charleroi, Erasme University Hospital, Grand Hôpital de Charleroi, KU Leuven, Universitair Ziekenhuis Brussel, University Hospital, Ghent, University of Liege

Country where clinical trial is conducted

Belgium, 

Outcome

Type Measure Description Time frame Safety issue
Primary Efficacy on asthma symptoms Asthma Control Test: 5 items of score 1 to 5 about symptoms, with result of 20 or above indicates good control; 15 to 19 indicates no good control and below 15 indicates no control at all, and a change of 3 points considered as clinically significant. Up to 22 months
Primary Efficacy on lung function Lung function measured as forced expiratory volume in one sec (FEV1), % predicted value (normal value of 80% predicted or above, and change of 100 mL considered as clinically significant). Up to 22 months
Primary Efficacy on severe exacerbations Number of exacerbation(s) per period of time (corrected per year) requiring systemic corticosteroid treatment for at least 3 days, and/or emergency visit or hospitalization for acute asthma. Up to 22 months
Secondary Predictive factors of therapeutic response The putative predictive factors of therapeutic response to omalizumab or mepolizumab which will be assayed are the following: age at onset, year (> or < 30yrs); presence of nasal polyps, Y/N; blood eosinophils, n/microliter (< or > 300/microl); serum total IgE, units/L; serum periostin, ng/ml. A proteomic analysis will also be carried out on plasma samples. Baseline features (and according to response at 22 months)
See also
  Status Clinical Trial Phase
Recruiting NCT05018299 - Evaluate the Efficacy and Safety of FB704A in Adult With Severe Asthma Phase 2
Recruiting NCT05472324 - Evaluate the Efficacy and Safety of TQC2731 Injection in Patients With Severe Asthma. Phase 2
Recruiting NCT04914078 - Severe Asthma Exacerbations and Mepolizumab Treatment
Completed NCT05576454 - Evaluate the Pharmacokinetics of BAT2606 Injection in Healthy Chinese Male Subjects Phase 1
Recruiting NCT04520165 - Effect of Biologicals on Alternative Functions of Eosinophils in Severe Asthma
Recruiting NCT04438408 - National Survey on Care Pathway and Quality of Life in Patients With Severe Asthma According to Their Phenotype.
Not yet recruiting NCT04463836 - Phenotyping Circulating and Lung Resident Eosinophils in Severe Asthma (P-CLESA)
Enrolling by invitation NCT06421402 - K-HEALTH in AIR - Barcelona Pilot - Cohort
Recruiting NCT03377920 - Predictive Value of Spirometric PIF to Produce PIF Rate Needed for the Use of Current DPI's. N/A
Recruiting NCT04565483 - Predictive Signature of Benralizumab Response Phase 4
Recruiting NCT04045587 - International Severe Asthma Registry: Canadian Cohort
Completed NCT05616338 - Modeling Bronchial Epithelium in Severe Asthma With Human Induced Pluripotent Stem Cells (iPSC) N/A
Active, not recruiting NCT02038374 - Clinico-biological Correlation of Severe Asthma in Children N/A
Active, not recruiting NCT02114034 - Cohort Analysis of Clinical and Biological Severe Childhood Asthma
Recruiting NCT06035289 - Register Schweres Asthma - German Asthma Net e.V.
Not yet recruiting NCT03532685 - Clinical, Inflammatory and Functional Evaluation of a Population of Severe and Obese Asthmatics: Follow up N/A
Completed NCT03931954 - Prevalence of the Eosinophilic Phenotype Among Severe Asthma Patients
Recruiting NCT03984253 - Swiss Severe Asthma Register
Recruiting NCT03435237 - Phenotyping Asthma for Bronchial Thermoplasty
Active, not recruiting NCT06389058 - Using NLP and Neural Networks to Autonomously Identify Severe Asthma and Determine Study Eligibility in a Large Healthcare System